One, two, three, exhale: Europe’s vaccination supplies are on track

Visual form

Two-part vaccine-supply chart combining icon grids and a supply-under-contract panel.

Layout / body structure

The chart starts with two 10-by-10 icon grids at the top comparing the share of EU adults who can be vaccinated by the end of Q1 and the end of Q2. Beneath that sits a wide supply-under-contract panel made of large labeled diamonds for individual manufacturers, split between conditionally authorized and not yet authorized courses.

What is being compared

It compares the share of the EU adult population that can be vaccinated at two points in time and the mix of vaccine courses under contract from different manufacturers. The lower panel separates authorized suppliers from those not yet authorized while also summing the total contracted supply.

Measurement system

The top measure is percent of EU adults who can be vaccinated, shown as 14 percent at the end of Q1 and 68 percent at the end of Q2 through filled icon grids. The lower measure is millions of courses under contract, with labeled diamonds for Johnson and Johnson, Pfizer-BioNTech, Moderna, AstraZeneca, CureVac, Sanofi-GSK, Novavax, and Valneva.

Visible structure inside the graphic

The top icon arrays use the same 100-cell grid so the jump from a small dark band at the end of Q1 to a much fuller dark block by the end of Q2 is immediate. The lower panel arranges the supplier totals as a left-to-right row of diamonds, with dark authorized suppliers on the left and lighter not-yet-authorized suppliers on the right, plus large summary totals printed above and below.

Main takeaway from the visual

Europe’s contracted vaccine supply appears sufficient to vaccinate most adults by mid-2021, even though not all of the doses are yet authorized. The chart makes this credible by pairing the large contracted-course totals with the much fuller end-of-Q2 vaccination grid.

Key standout values or extremes

The top grids show 14 vaccinated at the end of Q1 and 68 vaccinated at the end of Q2. In the lower panel, conditionally authorized supply totals 1,130 million courses, not-yet-authorized supply totals 483 million, and the overall pool is about 1,600 million; the largest named suppliers shown are Johnson and Johnson at 400, Pfizer-BioNTech at 300, Moderna at 230, and AstraZeneca at 200.

Controls / sequence, when applicable

This is a static chart image with no in-chart controls to operate.

Companion media, when applicable

There is no separate companion audio or video; the chart image is the full visual on this page.